LENZ PE Ratio & Valuation,Is LENZ Overvalued

LENZ Relative Valuation

LENZ's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LENZ is overvalued; if below, it's undervalued.

Historical Valuation

LENZ Therapeutics Inc (LENZ) is now in the Undervalued zone, suggesting that its current forward PS ratio of 20.27 is considered Undervalued compared with the five-year average of -10.51. The fair price of LENZ Therapeutics Inc (LENZ) is between 26.13 to 92.87 according to relative valuation methord. Compared to the current price of 18.14 USD , LENZ Therapeutics Inc is Undervalued By 30.57%.

Relative Value

Fair Zone

26.13-92.87

Current Price：18.14

30.57%

Undervalued

-5.61

-4.74

EV/EBITDA

LENZ Therapeutics Inc. (LENZ) has a current EV/EBITDA of -4.74. The 5-year average EV/EBITDA is -8.50. The thresholds are as follows: Strongly Undervalued below -14.41, Undervalued between -14.41 and -11.45, Fairly Valued between -5.55 and -11.45, Overvalued between -5.55 and -2.59, and Strongly Overvalued above -2.59. The current Forward EV/EBITDA of -4.74 falls within the Overvalued range.

-3.52

EV/EBIT

LENZ Therapeutics Inc. (LENZ) has a current EV/EBIT of -3.52. The 5-year average EV/EBIT is -7.06. The thresholds are as follows: Strongly Undervalued below -11.23, Undervalued between -11.23 and -9.14, Fairly Valued between -4.97 and -9.14, Overvalued between -4.97 and -2.89, and Strongly Overvalued above -2.89. The current Forward EV/EBIT of -3.52 falls within the Overvalued range.

20.27

LENZ Therapeutics Inc. (LENZ) has a current PS of 20.27. The 5-year average PS is 50.65. The thresholds are as follows: Strongly Undervalued below -42.56, Undervalued between -42.56 and 4.05, Fairly Valued between 97.26 and 4.05, Overvalued between 97.26 and 143.87, and Strongly Overvalued above 143.87. The current Forward PS of 20.27 falls within the Historic Trend Line -Fairly Valued range.

-9.40

P/OCF

LENZ Therapeutics Inc. (LENZ) has a current P/OCF of -9.40. The 5-year average P/OCF is -11.36. The thresholds are as follows: Strongly Undervalued below -18.38, Undervalued between -18.38 and -14.87, Fairly Valued between -7.84 and -14.87, Overvalued between -7.84 and -4.33, and Strongly Overvalued above -4.33. The current Forward P/OCF of -9.40 falls within the Historic Trend Line -Fairly Valued range.

-4.01

P/FCF

LENZ Therapeutics Inc. (LENZ) has a current P/FCF of -4.01. The 5-year average P/FCF is -8.96. The thresholds are as follows: Strongly Undervalued below -13.85, Undervalued between -13.85 and -11.40, Fairly Valued between -6.51 and -11.40, Overvalued between -6.51 and -4.07, and Strongly Overvalued above -4.07. The current Forward P/FCF of -4.01 falls within the Strongly Overvalued range.

LENZ Therapeutics Inc (LENZ) has a current Price-to-Book (P/B) ratio of 2.67. Compared to its 3-year average P/B ratio of 3.60 , the current P/B ratio is approximately -25.79% higher. Relative to its 5-year average P/B ratio of 3.60, the current P/B ratio is about -25.79% higher. LENZ Therapeutics Inc (LENZ) has a Forward Free Cash Flow (FCF) yield of approximately -8.13%. Compared to its 3-year average FCF yield of -9.41%, the current FCF yield is approximately -13.60% lower. Relative to its 5-year average FCF yield of -9.41% , the current FCF yield is about -13.60% lower.

2.67

P/B

Median3y

3.60

Median5y

3.60

-8.13

FCF Yield

Median3y

-9.41

Median5y

-9.41

Competitors Valuation Multiple

The average P/S ratio for LENZ's competitors is 64.81, providing a benchmark for relative valuation. LENZ Therapeutics Inc Corp (LENZ) exhibits a P/S ratio of 20.27, which is -68.73% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of LENZ increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of LENZ in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is LENZ Therapeutics Inc (LENZ) currently overvalued or undervalued?

What is LENZ Therapeutics Inc (LENZ) fair value?

LENZ's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of LENZ Therapeutics Inc (LENZ) is between 26.13 to 92.87 according to relative valuation methord.

How does LENZ's valuation metrics compare to the industry average?

What is the current P/B ratio for LENZ Therapeutics Inc (LENZ) as of Dec 15 2025?

As of Dec 15 2025, LENZ Therapeutics Inc (LENZ) has a P/B ratio of 2.67. This indicates that the market values LENZ at 2.67 times its book value.

What is the current FCF Yield for LENZ Therapeutics Inc (LENZ) as of Dec 15 2025?

As of Dec 15 2025, LENZ Therapeutics Inc (LENZ) has a FCF Yield of -8.13%. This means that for every dollar of LENZ Therapeutics Inc’s market capitalization, the company generates -8.13 cents in free cash flow.

What is the current Forward P/E ratio for LENZ Therapeutics Inc (LENZ) as of Dec 15 2025?

As of Dec 15 2025, LENZ Therapeutics Inc (LENZ) has a Forward P/E ratio of -5.61. This means the market is willing to pay $-5.61 for every dollar of LENZ Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for LENZ Therapeutics Inc (LENZ) as of Dec 15 2025?

As of Dec 15 2025, LENZ Therapeutics Inc (LENZ) has a Forward P/S ratio of 20.27. This means the market is valuing LENZ at $20.27 for every dollar of expected revenue over the next 12 months.

LENZ Valuation